AI Tools Are Getting FDA Attention—and Investors Are Taking Note
Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – The World Economic Forum recently released another video on 5 major healthcare advances, with the top advancements coming from AI, through AI-powered surgery, AI-aided detection, adaptive deep brain stimulation, heart monitors, and detecting more than 1,000 diseases. Almost the entire healthcare sector is being revamped with AI enhancements, fueling innovation and efficiency along the way. Powering these advancements are innovators in both biotech, and even healthcare and insurance providers, with recent developments coming from Avant Technologies, Inc. (OTCQB: AVAI), UnitedHealth Group Incorporated (NYSE: UNH), Clover Health Investments, Corp. (NASDAQ: CLOV), Medtronic plc (NYSE: MDT), and Becton, Dickinson and Company (NYSE: BDX).
The article continued: Recently private company Pathos AI secured $365 million in Series D financing to advance cancer drug development through AI. Industry analysts at MarketsandMarkets project that the AI in healthcare market will expand at a compound annual growth rate of 38.6%, reaching over $110 billion by 2030.
Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting
Avant Technologies, Inc. (OTCQB: AVAI), an emerging player in AI-driven healthcare innovation, and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. If successful, it’s a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient’s data.
Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company’s signature AI- driven Vision AI technology platform.
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company’s aim to continue to add to its portfolio, “Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily. We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.
“To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”
Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report.
Vargas added, “We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry.”
Avant will inform its shareholders of any updates at an appropriate time.
Most recently, Avant began official talks of a proposed acquisition of Ainnova, officially unifying operations of the two parties into one, after already aligning under the Ai-nova Acquisition Corp. (AAC) banner. This intentional step came just ahead of their scheduled FDA pre-submission meeting this July. If completed, the merger would remove internal friction, streamline clinical trial planning, and strengthen their regulatory posture ahead of potential U.S. market entry.
“We believe bringing the two companies together will offer tremendous value for shareholders,” said Vargas. “It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.”
At the core of this effort is the previously mentioned Vision AI, a non-invasive clinical screening platform that combines retinal imaging, vital sign capture, and machine-learning algorithms to detect early signals of chronic illness—including diabetic retinopathy, cardiovascular disease, kidney and liver conditions, and type 2 diabetes. Operating under AAC, the joint venture holds global rights to the platform, which has shown more than 90% sensitivity in early detection, according to NIH-cited research.
"This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vargas. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."
While many AI-driven healthcare ventures remain in the pilot or proof-of-concept phase, Avant’s platform is already in deployment across multiple Latin American markets—including Chile, Mexico, and Brazil—where it continues to operate in live clinical environments. These real-world settings are generating critical data on both safety and efficacy, while also supplying user feedback that informs ongoing refinements to performance and usability.
To expand its diagnostic range, the Ai-nova joint venture recently added four new algorithms to the Vision AI platform. Each was trained on a dataset exceeding 2.3 million clinical cases, enhancing the system’s capabilities across a broader array of chronic diseases. With growing momentum overseas and regulatory planning underway in the U.S., Avant’s story may soon shift from early promise to broader market relevance.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
UnitedHealth Group Incorporated (NYSE: UNH) has now deployed over 1,000 artificial intelligence applications across its insurance, care delivery, and pharmacy businesses, with use cases ranging from claim support to patient diagnostics.
“AI is the most exciting technology,” said Sandeep Dadlani, Chief Digital and Technology Officer at UnitedHealth Group. “But my job is to help really be practical and pragmatic, ambitious, and yet very responsible with this.”
About half of these tools leverage generative AI, including chatbots, documentation assistance, and data summarization aimed at improving efficiency and access. The company emphasizes that AI is used to augment—not replace—human decision-making, particularly in the claims process.
Clover Health Investments, Corp. (NASDAQ: CLOV), through its AI-driven subsidiary, Counterpart Health, has released new data showing that use of its Counterpart Assistant platform is associated with significantly better outcomes in patients with congestive heart failure (CHF).
“Counterpart Assistant is a testament to this commitment, offering clinicians actionable intelligence that can translate to improved care for patients with heart failure and a significant decrease in costly acute episodes,” said Conrad Wai, CEO of Counterpart Health. “This technology demonstrates that enhanced clinical quality and reduced cost of care delivery are not mutually exclusive, but rather, achievable through intelligent physician enablement.”
Patients managed by primary care physicians using the tool saw an 18% reduction in all-cause hospitalizations and a 25% drop in 30-day readmissions. The platform provides real-time, data-driven insights to support earlier diagnosis, guideline-based treatment, and improved coordination with specialists.
Medtronic plc (NYSE: MDT) has received FDA approval for its Adaptive Deep Brain Stimulation (aDBS) system, an AI-powered advancement that uses brainwave sensing to automatically adjust stimulation in real time for Parkinson’s patients.
"The aDBS system listens to these brain waves and then algorithms adjust the stimulation in real time according to what the brain waves tell us about their symptoms," said Dr. Simon Little, a neurologist at the University of California San Francisco. "It's a very exciting development."
Unlike traditional DBS devices that require manual reprogramming, aDBS interprets neural signals and modulates therapy to match the patient’s fluctuating needs throughout the day. This marks a pivotal step forward in neuromodulation, combining real-time data with AI algorithms to improve quality of life in chronic disease management.
Becton, Dickinson and Company (NYSE: BDX) has launched the HemoSphere Alta™, an advanced hemodynamic monitoring platform that integrates AI-driven algorithms to help clinicians proactively manage blood flow and blood pressure instability during procedures. The platform features predictive tools like the Hypotension Prediction Index and a novel Cerebral Autoregulation Index, offering personalized insights into each patient’s cerebral blood flow regulation. With these capabilities, clinicians can detect and respond to risks earlier, improving outcomes and minimizing complications.
CONTACT:
Baystreet.ca
(250) 661-3391
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
